LivaNova plc Aktie
51,00 €
Deine Einschätzung
LivaNova plc Aktie
Was spricht für und gegen LivaNova plc in den nächsten Jahren?
Pro
Kontra
Rendite von LivaNova plc im Vergleich
Wertpapier | Ver.(%) | 1W | 1M | 1J | YTD | 3J | 5J |
---|---|---|---|---|---|---|---|
LivaNova plc | 2,82 % | -2,75 % | -2,75 % | 28,50 % | 5,98 % | -20,64 % | -41,99 % |
Neogen Corp. | 2,92 % | -2,84 % | -13,29 % | -17,96 % | -25,14 % | -62,21 % | -44,08 % |
Bio-Rad Labs Inc. A | -0,37 % | -1,17 % | 5,33 % | -23,86 % | 9,13 % | -32,41 % | - |
Merit Medical Systems | 0,72 % | 3,73 % | -4,79 % | 5,30 % | 2,21 % | 49,78 % | 31,16 % |
Kommentare
News
LivaNova to Announce First-Quarter 2024 Results
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, will host a conference call to discuss its first-quarter 2024 results on Wednesday, May 1, 2024 at 1 p.m. London time (8
LivaNova Announces a Positive Predictive Outcome of Trial Success in its OSPREY Clinical Study for Moderate to Severe Obstructive Sleep Apnea
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced its OSPREY clinical study, Treating Obstructive Sleep Apnea Using Targeted Hypoglossal Nerve Stimulation
LivaNova Announces Pricing of Private Offering of $300 Million of 2.50% Convertible Senior Notes Due 2029
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced the pricing of $300 million aggregate principal amount of 2.50% convertible senior notes due 2029 (the